Inhibiting matrix metalloproteinase by cell-based Timp-3 gene transfer effectively treats acute and chronic ischemic cardiomyopathy

Cell Transplantation

Volumn 21, Issue 5, 2012, Pages 1039-1053

  Tian, Hai ^a,b   Huang, Ming Li ^b   Liu, Kai Yu ^a,b   Jia, Zhi Bo ^a,b   Sun, Lu ^a,b   Jiang, Shu Lin ^a,b   Liu, Wei ^b   Kinkaid, Heather Y McDonald ^c   Wu, Jun ^c   Li, Ren Ke ^c  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cell based gene therapy; Extracellular matrix remodeling; Myocardial infarction (MI); Tissue inhibitors of matrix metalloproteinases (TIMPs)

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA;

ACUTE ISCHEMIC CARDIOMYOPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL BASED GENE THERAPY; CHRONIC ISCHEMIC CARDIOMYOPATHY; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE TRANSFER; HEART FUNCTION; ISCHEMIC CARDIOMYOPATHY; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL; UPREGULATION;

ACUTE DISEASE; ANIMALS; APOPTOSIS; CELLS, CULTURED; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLES; INFLAMMATION; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; SURVIVAL RATE; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE THERAPY; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862518189     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368911X601000     Document Type: Article

References (33)

1. Amour, A.; Slocombe, P. M.; Webster, A.; Butler, M.; Knight, C. G.; Smith, B. J.; Stephens, P. E.; Shelley, C.; Hutton, M.; Knauper, V.; Docherty, A. J.; Murphy, G. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435:39-44; 1998.
2. Angoulvant, D.; Fazel, S.; Weisel, R. D.; Lai, T. Y.; Fedak, P. W.; Chen, L.; Rafati, S.; Seneviratne, C. K.; Degousee, N.; Li, R. K. Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3-deficient mice. J. Thorac. Cardiovasc. Surg. 137:471-480; 2009.
3. Cargnoni, A.; Di Marcello, M.; Campagnol, M.; Nassuato, C.; Albertini, A.; Parolini, O. Amniotic membrane patching promotes ischemic rat heart repair. Cell Transplant. 18:1147-1159; 2009.
4. Degousee, N.; Ghomashchi, F.; Stefanski, E.; Singer, A.; Smart, B. P.; Borregaard, N.; Reithmeier, R.; Lindsay, T. F.; Lichtenberger, C.; Reinisch, W.; Lambeau, G.; Arm, J.; Tischfield, J.; Gelb, M. H.; Rubin, B. B. Groups IV, V, and X phospholipases A2s in human neutrophils: Role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J. Biol. Chem. 277:5061-5073; 2002.
5. Ducharme, A.; Frantz, S.; Aikawa, M.; Rabkin, E.; Lindsey, M.; Rohde, L. E.; Schoen, F. J.; Kelly, R. A.; Werb, Z.; Libby, P.; Lee, R. T. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 106:55-62; 2000.
6. Farahmand, P.; Lai, T. Y.; Weisel, R. D.; Fazel, S.; Yau, T.; Menasche, P.; Li, R. K. Skeletal myoblasts preserve remote matrix architecture and global function when implanted early or late after coronary ligation into infarcted or remote myocardium. Circulation 118:S130-S137; 2008.
7. Fazel, S.; Chen, L.; Weisel, R. D.; Angoulvant, D.; Seneviratne, C.; Fazel, A.; Cheung, P.; Lam, J.; Fedak, P. W.; Yau, T. M.; Li, R. K. Cell transplantation preserves cardiac function after infarction by infarct stabilization: Augmentation by stem cell factor. J. Thorac. Cardiovasc. Surg. 130:1310; 2005.
8. Fazel, S.; Cimini, M.; Chen, L.; Li, S.; Angoulvant, D.; Fedak, P.; Verma, S.; Weisel, R. D.; Keating, A.; Li, R. K. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest. 116:1865-1877; 2006.
9. Fedak, P. W.; Altamentova, S. M.; Weisel, R. D.; Nili, N.; Ohno, N.; Verma, S.; Lee, T. Y.; Kiani, C.; Mickle, D. A.; Strauss, B. H.; Li, R. K. Matrix remodeling in experimental and human heart failure: A possible regulatory role for TIMP-3. Am. J. Physiol. Heart Circ. Physiol. 284:H626-H634; 2003.
10. Fedak, P. W.; Smookler, D. S.; Kassiri, Z.; Ohno, N.; Leco, K. J.; Verma, S.; Mickle, D. A.; Watson, K. L.; Hojilla, C. V.; Cruz, W.; Weisel, R. D.; Li, R. K.; Khokha, R. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110:2401-2409; 2004.
11. Fedak, P. W.; Szmitko, P. E.; Weisel, R. D.; Altamentova, S. M.; Nili, N.; Ohno, N.; Verma, S.; Fazel, S.; Strauss, B. H.; Li, R. K. Cell transplantation preserves matrix homeostasis: a novel paracrine mechanism. J. Thorac. Cardiovasc. Surg. 130:1430-1439; 2005.
12. Hudson, M. P.; Armstrong, P. W.; Ruzyllo, W.; Brum, J.; Cusmano, L.; Krzeski, P.; Lyon, R.; Quinones, M.; Theroux, P.; Sydlowski, D.; Kim, H. E.; Garcia, M. J.; Jaber, W. A.; Weaver, W. D. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J. Am. Coll. Cardiol. 48:15-20; 2006.
13. Kiani, C.; Lee, V.; Cao, L.; Chen, L.; Wu, Y.; Zhang, Y.; Adams, M. E.; Yang, B. B. Roles of aggrecan domains in biosynthesis, modification by glycosaminoglycans and product secretion. Biochem. J. 354:199-207; 2001.
14. Kim, C.; Li, R. K.; Li, G.; Zhang, Y.; Weisel, R. D.; Yau, T. M. Effects of cell-based angiogenic gene therapy at 6 months: Persistent angiogenesis and absence of oncogenicity. Ann. Thorac. Surg. 83:640-646; 2007.
15. Kim, H. E.; Dalal, S. S.; Young, E.; Legato, M. J.; Weisfeldt, M. L.; D'Armiento, J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J. Clin. Invest. 106:857-866; 2000.
16. Li, R. K.; Mickle, D. A.; Weisel, R. D.; Rao, V.; Jia, Z. Q. Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury. Ann. Thorac. Surg. 72:1957-1963; 2001.
17. Li, R. K.; Mickle, D. A.; Weisel, R. D.; Zhang, J.; Mohabeer, M. K. In vivo survival and function of transplanted rat cardiomyocytes. Circ. Res. 78:283-288; 1996.
18. Li, T. S.; Takahashi, M.; Ohshima, M.; Qin, S. L.; Kubo, M.; Muramatsu, K.; Hamano, K. Myocardial repair achieved by the intramyocardial implantation of adult cardiomyocytes in combination with bone marrow cells. Cell Transplant. 17:695-703; 2008.
19. Liu, T. B.; Fedak, P. W.; Weisel, R. D.; Yasuda, T.; Kiani, G.; Mickle, D. A.; Jia, Z. Q.; Li, R. K. Enhanced IGF-1 expression improves smooth muscle cell engraftment after cell transplantation. Am. J. Physiol. Heart Circ. Physiol. 287:H2840-H2849; 2004.
20. Mangi, A. A.; Noiseux, N.; Kong, D.; He, H.; Rezvani, M.; Ingwall, J. S.; Dzau, V. J. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 9:1195-1201; 2003.
21. McMurray, J.; Pfeffer, M. A. New therapeutic options in congestive heart failure: Part I. Circulation 105:2099-2106; 2002.
22. Mukherjee, R.; Brinsa, T. A.; Dowdy, K. B.; Scott, A. A.; Baskin, J. M.; Deschamps, A. M.; Lowry, A. S.; Escobar, G. P.; Lucas, D. G.; Yarbrough, W. M.; Zile, M. R.; Spinale, F. G. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 107:618-625; 2003.
23. Nelson, A. R.; Fingleton, B.; Rothenberg, M. L.; Matrisian, L. M. Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol. 18:1135-1149; 2000.
24. Peterson, J. T.; Li, H.; Dillon, L.; Bryant, J. W. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc. Res. 46:307-315; 2000.
25. Spinale, F. G.; Escobar, G. P.; Hendrick, J. W.; Clark, L. L.; Camens, S. S.; Mingoia, J. P.; Squires, C. G.; Stroud, R. E.; Ikonomidis, J. S. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: Differential effects on short and long-term survival. J. Pharmacol. Exp. Ther. 318:966-973; 2006.
26. Sun, M.; Dawood, F.; Wen, W. H.; Chen, M.; Dixon, I.; Kirshenbaum, L. A.; Liu, P. P. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 110:3221-3228; 2004.
27. Sun, Z.; Wu, J.; Fujii, H.; Wu, J.; Li, S. H.; Porozov, S.; Belleli, A.; Fulga, V.; Porat, Y.; Li, R. K. Human angiogenic cell precursors restore function in the infarcted rat heart: A comparison of cell delivery routes. Eur. J. Heart Fail. 10:525-533; 2008.
28. Tian, H.; Cimini, M.; Fedak, P. W.; Altamentova, S.; Fazel, S.; Huang, M. L.; Weisel, R. D.; Li, R. K. TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J. Mol. Cell. Cardiol. 43:733-743; 2007.
29. Vu, T. H.; Werb, Z. Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev. 14: 2123-2133; 2000.
30. Webb, C. S.; Bonnema, D. D.; Ahmed, S. H.; Leonardi, A. H.; McClure, C. D.; Clark, L. L.; Stroud, R. E.; Corn, W. C.; Finklea, L.; Zile, M. R.; Spinale, F. G. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: Relation to left ventricular remodeling. Circulation 114:1020-1027; 2006.
31. Woessner, Jr., J. F. That impish TIMP: The tissue inhibitor of metalloproteinases-3. J. Clin. Invest. 108:799-800; 2001.
32. Yau, T. M.; Kim, C.; Li, G.; Zhang, Y.; Fazel, S.; Spiegelstein, D.; Weisel, R. D.; Li, R. K. Enhanced angio-genesis with multimodal cell-based gene therapy. Ann. Thorac. Surg. 83:1110-1119; 2007.
33. Yau, T. M.; Kim, C.; Li, G.; Zhang, Y.; Weisel, R. D.; Li, R. K. Maximizing ventricular function with multi-modal cell-based gene therapy. Circulation 112:I123-I128; 2005.